ArticleVaccine2025

Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201.

Anna R Giuliano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.